USANA Health Sciences Inc. (USNA) Rating Lowered to Hold at Zacks Investment Research
USANA Health Sciences Inc. (NYSE:USNA) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “
Separately, DA Davidson upped their price target on shares of USANA Health Sciences from $135.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, July 28th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $149.11.
USANA Health Sciences (NYSE:USNA) traded up 0.74% during midday trading on Wednesday, reaching $136.88. 20,995 shares of the company’s stock were exchanged. USANA Health Sciences has a 52 week low of $92.00 and a 52 week high of $142.96. The stock’s 50 day moving average is $135.93 and its 200 day moving average is $125.31. The firm has a market capitalization of $1.65 billion, a P/E ratio of 18.04 and a beta of 1.16.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.02. The firm had revenue of $258.50 million for the quarter, compared to analysts’ expectations of $256.66 million. USANA Health Sciences had a net margin of 10.07% and a return on equity of 34.15%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.92 earnings per share. On average, analysts expect that USANA Health Sciences will post $8.10 EPS for the current fiscal year.
In other USANA Health Sciences news, insider Kevin Guest sold 16,285 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $131.08, for a total transaction of $2,134,637.80. Following the sale, the insider now directly owns 16,285 shares of the company’s stock, valued at $2,134,637.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Global Ltd Gull sold 10,000 shares of the stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $118.96, for a total transaction of $1,189,600.00. Following the sale, the insider now directly owns 6,349,110 shares in the company, valued at $755,290,125.60. The disclosure for this sale can be found here. Company insiders own 57.00% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada boosted its stake in shares of USANA Health Sciences by 25.2% in the second quarter. Royal Bank of Canada now owns 3,080 shares of the company’s stock worth $344,000 after buying an additional 620 shares during the period. Calvert Investment Management Inc. purchased a new position in USANA Health Sciences during the second quarter valued at approximately $789,000. Legal & General Group Plc raised its position in USANA Health Sciences by 30.9% in the second quarter. Legal & General Group Plc now owns 1,696 shares of the company’s stock valued at $186,000 after buying an additional 400 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in USANA Health Sciences during the second quarter valued at approximately $305,000. Finally, Cantab Capital Partners LLP raised its position in USANA Health Sciences by 39.1% in the second quarter. Cantab Capital Partners LLP now owns 4,046 shares of the company’s stock valued at $451,000 after buying an additional 1,138 shares in the last quarter. 41.86% of the stock is currently owned by institutional investors.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.